Study: Oral CBD Use Has Anxiolytic and Anti-Psychotic Activity

Study: Oral CBD Use Has Anxiolytic and Anti-Psychotic Activity

The oral administration of purified CBD is associated with anxiolytic and anti-psychotic activity while possessing few adverts side-effects. This is according to a study published in the Journal of Clinical Medicine Research and epublished by the U.S. National Institute of Health.

For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. They found that “There is some evidence that supports anxiolytic effect of acute administration of oral CBD. There is moderate-quality evidence that chronic and acute administration of CBD can improve psychotic symptoms in schizophrenia patients.” 

“[M]ost studies reported no adverse events with acute administration and mild to moderate adverse effects with chronic administration. In comparison to other drugs, a better side effect profile was presented.”

The study is titled Dosage, efficacy, and safety of cannabidiol administration in adults: A systematic review of human trials.

The study’s abstract can be found below:

Considering data from in vitro and in vivo studies, cannabidiol (CBD) seems to be a promising candidate for the treatment of both somatic and psychiatric disorders. The aim of this review was to collect dose(s), dosage schemes, efficacy and safety reports of CBD use in adults from clinical studies. A systematic search was performed in PubMed, Embase and Cochrane library for articles published in English between January 1, 2000 and October 25, 2019. The search terms used were related to cannabis and CBD in adults. We identified 25 studies (927 patients; 538 men and 389 women), of which 22 studies were controlled clinical trials (833 patients) and three were observational designs (94 patients) from five countries. Formulations, dose and dosage schemes varied significantly between studies. Varying effects were identified from the randomized controlled trials (RCTs), more apparent effects from non-RCTs and minor safety issues in general. From the controlled trials, we identified anxiolytic effects with acute CBD administration, and therapeutic effects for social anxiety disorder, psychotic disorder and substance use disorders. In general, studies were heterogeneous and showed substantial risks of bias. Although promising results have been identified, considerable variation in dosage schemes and route of administration were employed across studies. There was evidence to support single dose positive effect on social anxiety disorder, short medium-term effects on symptomatic improvement in schizophrenia and lack of effect in the short medium-term on cognitive functioning in psychotic disorders. Overall, the administration was well tolerated with mild side effects.